Moderna, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation and amortization $20.5m $24.9m $31.0m $31.3m $232.0m $348.0m $621.0m $189.0m $215.0m
Amortization/accretion of investments $1.1m ($1.9m) ($3.7m) $10.2m $54.0m $31.0m ($61.0m) ($95.0m) ($67.0m)
Loss on equity investments, net $0 $0 $35.0m $52.0m $8.0m
Right-of-use assets, operating leases $0 ($5.7m) ($10.5m) ($58.0m) $21.0m ($605.0m) ($53.0m) $38.0m
Operating lease liabilities $0 $12.6m $11.8m $17.0m ($14.0m) $551.0m $28.0m ($21.0m)
Net loss ($255.9m) ($384.7m) ($514.0m) ($747.1m) $12.2b $8.4b ($4.7b) ($3.6b) ($2.8b)
Stock-based compensation $40.1m $72.6m $81.1m $93.0m $142.0m $226.0m $305.0m $429.0m $483.0m
Other non-cash items $0 $0 $28.0m $7.0m $60.0m $77.0m
Accounts receivable, net $1.5m $195k $6.7m ($1.4b) ($1.8b) $1.8b $493.0m $534.0m $156.0m
Prepaid expenses and other assets $579k ($5.3m) $9.8m ($241.0m) ($489.0m) ($1.7b) $974.0m $145.0m $153.0m
Inventory $0 $0 ($46.5m) ($1.4b) $492.0m $747.0m $83.0m ($34.0m)
Accounts payable ($12.8m) $15.0m ($24.0m) $11.9m $204.0m $240.0m $13.0m ($69.0m) ($92.0m)
Accrued liabilities $34.4m $8.8m ($3.4m) $388.4m $989.0m $612.0m ($340.0m) ($385.0m) ($2.0m)
Deferred revenue ($162.3m) ($65.3m) ($44.1m) $3.8b $2.8b ($4.2b) ($2.1b) ($439.0m) $41.0m
Other liabilities ($145k) $910k ($6.2m) $6.0m $123.0m $88.0m $73.0m $78.0m ($6.0m)
Purchases of marketable securities ($727.2m) ($1.2b) ($1.1b) ($3.0b) ($12.7b) ($11.4b) ($3.8b) ($6.5b) ($5.8b)
Proceeds from maturities of marketable securities $800.4m $783.4m $993.2m $1.1b $1.3b $3.2b $5.6b $5.6b $5.6b
Proceeds from sales of marketable securities $402.5m $177.0m $168.7m $214.7m $3.1b $3.5b $3.2b $4.0b $2.4b
Purchase of intangible asset $0 $0 ($10.0m)
Investment in convertible notes and equity securities $0 $0 ($30.0m) ($40.0m) ($23.0m) $0 $0
Proceeds from credit facility $0 $0 $600.0m
Payment of credit facility issuance costs $0 $0 ($22.0m)
Tax payments related to net share settlements on equity awards $0 $0 ($857.0m) ($3.3b) ($1.2b) $0 ($2.0m)
Changes in financing lease liabilities $1.0m ($6.0m) ($140.0m) ($184.0m) ($270.0m) ($10.0m) ($18.0m)
Purchases of property, plant and equipment included in accounts payable and accrued liabilities $20.0m $12.9m $4.7m $17.6m $111.0m $72.0m $130.0m $97.0m $83.0m
Net cash used in operating activities ($331.5m) ($330.9m) ($459.0m) $2.0b $13.6b $5.0b ($3.1b) ($3.0b) ($1.9b)
Purchases of property, plant and equipment ($58.4m) ($105.8m) ($31.6m) ($67.4m) ($284.0m) ($400.0m) ($707.0m) ($1.1b) ($192.0m)
Acquisition of business, net of cash acquired $0 $0 ($85.0m) $0 $0
Net cash provided by investing activities $417.4m ($373.1m) ($14.9m) ($1.7b) ($8.5b) ($5.2b) $4.2b $1.9b $1.9b
Proceeds from issuance of common stock through equity plans $212k $1.4m $47.3m $179.6m $124.0m $65.0m $46.0m $66.0m $35.0m
Net cash provided by (used in) financing activities $168k $1.2b $51.1m $2.0b ($873.0m) ($3.4b) ($1.4b) $56.0m $593.0m
Effect of changes in exchange rates on cash and cash equivalents $0 $0 $2.0m
Net increase (decrease) in cash, cash equivalents and restricted cash $86.0m $522.9m ($422.8m) $2.4b $4.2b ($3.6b) ($289.0m) ($999.0m) $668.0m
Cash, cash equivalents and restricted cash, beginning of year $147.6m $670.5m $247.7m $2.6b $6.9b $3.2b $2.9b $1.9b $2.6b
Cash paid for interest $0 $3.0m $0 $8.5m $14.0m $25.0m $39.0m $24.0m $10.0m
Cash paid (received) for income taxes $398k $294k $416k $572k $480.0m $2.7b ($357.0m) $197.0m $26.0m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.